Publication: Baseline and on-treatment predictors of chronic hepatitis B patients receiving pegylated interferon therapy in Asia
Issued Date
2013-09-01
Resource Type
ISSN
15410706
15403416
15403416
Other identifier(s)
2-s2.0-84881247607
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Current Hepatitis Reports. Vol.12, No.3 (2013), 165-173
Suggested Citation
Phunchai Charatcharoenwitthaya, Teerha Piratvisuth Baseline and on-treatment predictors of chronic hepatitis B patients receiving pegylated interferon therapy in Asia. Current Hepatitis Reports. Vol.12, No.3 (2013), 165-173. doi:10.1007/s11901-013-0175-5 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/31878
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Baseline and on-treatment predictors of chronic hepatitis B patients receiving pegylated interferon therapy in Asia
Other Contributor(s)
Abstract
Of currently available drugs for the treatment of chronic hepatitis B, pegylated interferon (peg-IFN) offers the highest rate of off-treatment sustained response with the finite course of treatment in the absence of viral resistance. However, its clinical use is compromised by the frequent occurrence of side-effects and the uncertainty as to whether a patient will actually benefit from this treatment. It is therefore a major challenge to identify accurate predictors of sustained response to peg-IFN. These are essential for selecting the optimal candidates for peg-IFN therapy, as well as for making decisions of termination of treatment for nonresponders. This article reviews the recent knowledge focusing on the following topics: baseline and on-treatment viral and host factors in the response to peg-IFN therapy, as well as response-guided therapy for chronic hepatitis B, particularly in the Asian population. © 2013 Springer Science+Business Media New York.